The cardiac pharmacodynamics of therapeutic doses of sparfloxacin

Autor: Mary Beth Dorr, Thomas Hunt, David Magner, Joel Morganroth, George H. Talbot
Rok vydání: 1999
Předmět:
Zdroj: Clinical Therapeutics. 21:1171-1181
ISSN: 0149-2918
DOI: 10.1016/s0149-2918(00)80020-x
Popis: This double-masked, randomized, placebo-controlled study assessed the cardiac safety of sparfloxacin (as measured by the effect on corrected QT [QT,] interval) at the extremes of the expected therapeutic dosage range. Ninety healthy adult male volunteers with no clinically relevant electrocardiographic (ECG) abnormalities received either placebo or 1 of 3 sparfloxacin regimens consisting of a loading dose on day 1 followed by 3 days of daily dosing at half the loading dose (200/100 mg, 400/200 mg, or 800/400 mg). After each dose, serial blood samples and ECG measurements were obtained to determine the pharmacokinetic and pharmacodynamic variables for sparfloxacin. Increases in the area under the plasma concentration-time curve from time 0 to 24 hours (AUC 0–24 ) for each dosing interval and in the maximum concentration (C max ) on days 1 and 4 were dose proportional. The steady-state (day-4) values were 6% to 16% lower than the day-1 values. At steady state, the time to C max ranged from 2.5 to 3.9 hours across all doses and days studied. The half-life ranged from 18.7 to 20.3 hours. Increases in the placebo-adjusted mean change and mean maximum change in QT c interval were dose related. The placebo-adjusted increases on day 1 were 9, 16, and 28 milliseconds after receipt of the 200/100-mg, 400/200-mg, and 800/400-mg regimens, respectively. The corresponding increases on day 4 were 7, 12, and 26 milliseconds. The placebo-adjusted changes in QT c interval also showed a linear relationship with the AUC 0–24 and C max of sparfloxacin. In the majority of volunteers (>90%), these increases were within the normal range for the QT c interval (≤460 milliseconds).
Databáze: OpenAIRE
Externí odkaz: